Varda Space Secured $250 Million Series D Funding

The orbital manufacturing firm reached a $1.6 billion valuation to expand its microgravity pharmaceutical production.

Updated on Sept. 30, 2026 in Biotech

Varda Space Secured $250 Million Series D Funding

Live Poll

Do you believe manufacturing medicines in space will lead to significant breakthroughs for the average person?

Varda Space closed a $250 million Series D funding round in September 2026, pushing the company to a $1.6 billion valuation. Based in El Segundo, the firm specializes in manufacturing pharmaceuticals within uncrewed orbital capsules.

Why it matters

The company produces high-purity pharmaceuticals in microgravity environments to increase efficiency. This capital injection supports its strategy to scale orbital manufacturing as a viable alternative to Earth-based drug development.

Varda Space has successfully deployed six orbital missions since 2023. Its manufacturing process involves re-entry speeds at 25 times the speed of sound to deliver research payloads.

The players

Varda Space

This El Segundo-based company designs and operates uncrewed spacecraft for pharmaceutical manufacturing in microgravity.

Lux Capital

This venture capital firm invests in emerging technologies and co-led the recent funding round for Varda Space.

Natural Capital

This investment firm focuses on scaling innovative companies and co-led the Series D round for Varda Space.

Mikael Dolsten

He is a prominent executive and researcher who was appointed to the Varda Space board in August 2026.

The details

Varda Space utilizes rideshare missions on SpaceX Falcon 9 rockets to launch its production capsules into Earth orbit. The company currently employs 275 people and plans to debut a next-generation manufacturing capsule by 2030.

Varda Space was founded in 2021.
The company began deploying orbital missions in 2023.
Mikael Dolsten joined the board in August 2026.
The Series D funding round officially closed in September 2026.
A next-generation capsule debut is planned for 2030.

The Tech Race

The reliance on SpaceX Falcon 9 rideshare missions enables Varda to scale orbital manufacturing capacity as a standard logistics backbone. This approach marks a shift from experimental space flight to recurring industrial production in orbit.

As Varda scales production, the eventual shift toward commercial pharmaceutical customers could lead to more efficient, high-purity medications reaching the market. Investors and industry observers can monitor these launches as indicators of long-term healthcare manufacturing costs.

The takeaway

Varda Space continues to prove that manufacturing in microgravity is a growing segment of the commercial space economy. The company remains focused on transitioning from government-heavy contracts to a more balanced commercial client base over the coming years.